Chronic Rhinosinusitis with Nasal Polyps
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old, gender not limited. 2. Meet the above diagnostic criteria for chronic sinusitis with nasal polyps. 3. The patient signed the informed consent form, voluntarily participated in this study, and was willing to abide by the requirements of the study protocol, cooperating to complete all examinations and follow-ups. 4. Be capable of understanding and correctly completing relevant scoring scales (such as NCS score, SNOT-22 score, etc.).
Exclusion criteria
Exclusion criteria: 1.Those who are allergic to secukinumab or its excipients. 2. There are serious underlying diseases that may affect the research results or patient safety, such as severe cardiovascular diseases (such as uncontrolled hypertension, unstable angina pectoris, myocardial infarction, etc.), liver and kidney dysfunction, hematological diseases, and neurological diseases. 3. Within the past three months, other biological agents have been used to treat chronic sinusitis with nasal polyps or other type 2 inflammation-related diseases. 4. Within the past month, systemic glucocorticoids (excluding the maintenance dose of inhaled glucocorticoids), immunosuppressants and other drugs that may affect the efficacy and safety assessment of the study drug have been used. 5. Those who suffer from mental illness and are unable to cooperate in completing research or signing the informed consent form. 6. Pregnant or lactating women. 7. Other circumstances where the researcher deems it unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasal Congestion Score,NCS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sino-Nasal Outcome Test-22;Visual Analogue Scale,VAS;Lund-Kennedy score of nasal endoscopy;Lund-Mackay score of paranasal sinus CT;Nasal Polyp Score,NPS;Evaluation of olfactory function; | — |
Countries
China
Contacts
Shanghai Tongji Hospital